3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Multiple Endocrine Neoplasia Type 2a
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Lethal Congenital Contracture Syndrome 2
1
Hematologic Neoplasms
1
Fallopian Tube Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Advanced Solid Tumor Malignancies
1
Advanced Solid Tumor
1
Interventions
tremelimumab
3
durvalumab
3
Ipilimumab
3
pembrolizumab
2
Nivolumab
2
Carboplatin
2
poly ICLC
1
osimertinib
1
lenvatinib
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Vaccination
1
Peptides
1
Pemetrexed
1
Paclitaxel
1
Monophenol Monooxygenase
1
Melphalan
1
Docetaxel
1
Axitinib
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Antibodies, Bispecific
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled